These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 37289594

  • 21. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A, Moonla C, Sosothikul D.
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [Abstract] [Full Text] [Related]

  • 22. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [Abstract] [Full Text] [Related]

  • 23. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S, Martinowitz U, Windyga J, Enriquez MM, Delesen H, Schwartz L, Scharrer I.
    Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
    [Abstract] [Full Text] [Related]

  • 24. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
    Vollack-Hesse N, Oleshko O, Werwitzke S, Solecka-Witulska B, Kannicht C, Tiede A.
    Blood; 2021 Feb 25; 137(8):1072-1081. PubMed ID: 32877516
    [Abstract] [Full Text] [Related]

  • 25. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E, Lavin M, Heck LA, Larkin N, Mullaney B, Doherty D, Kennedy M, Keenan C, Guest T, O'Mahony B, Fazavana J, Fallon PG, Preston RJS, Gormley J, Ryan K, O'Connell NM, Singleton E, Byrne M, McGowan M, Roche S, Doyle M, Crowley MP, O'Shea SI, Reipert BM, Johnsen JM, Pipe SW, Di Paola J, Turecek PL, O'Donnell JS, iPATH study group.
    J Thromb Haemost; 2023 May 25; 21(5):1123-1134. PubMed ID: 36775768
    [Abstract] [Full Text] [Related]

  • 26. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G, Ito J, Mercer R, Baldwin WH, Cox C, Parker ET, Healey JF, Lollar P, Meeks SL.
    J Thromb Haemost; 2018 Sep 25; 16(9):1779-1788. PubMed ID: 29981270
    [Abstract] [Full Text] [Related]

  • 27. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind.
    Hermans C, Pierce GF.
    J Thromb Haemost; 2024 Jul 25; 22(7):1844-1846. PubMed ID: 38679336
    [Abstract] [Full Text] [Related]

  • 28. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR, Tuller J, Johnson JA.
    Haemophilia; 1999 Mar 25; 5(2):88-95. PubMed ID: 10215955
    [Abstract] [Full Text] [Related]

  • 29. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S, Maro GS, Desai V, Simpson ML.
    J Manag Care Spec Pharm; 2020 Oct 25; 26(10):1258-1265. PubMed ID: 32820685
    [Abstract] [Full Text] [Related]

  • 30. Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.
    Gringeri A, Ofosu FA, Grancha S, Oldenburg J, Ewing NP, Federici AB.
    Haemophilia; 2012 May 25; 18(3):469-75. PubMed ID: 21943193
    [Abstract] [Full Text] [Related]

  • 31. Half-life extended factor VIII for the treatment of hemophilia A.
    Tiede A.
    J Thromb Haemost; 2015 Jun 25; 13 Suppl 1():S176-9. PubMed ID: 26149020
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB.
    Blood Coagul Fibrinolysis; 2005 Apr 25; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [Abstract] [Full Text] [Related]

  • 35. Treatment of von Willebrand disease.
    Rodeghiero F, Castaman G.
    Semin Hematol; 2005 Jan 25; 42(1):29-35. PubMed ID: 15662613
    [Abstract] [Full Text] [Related]

  • 36. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD, Kunz D, Wirtz DC.
    Am J Hematol; 2002 May 25; 70(1):64-71. PubMed ID: 11994985
    [Abstract] [Full Text] [Related]

  • 37. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
    van Moort I, Bukkems LH, Heijdra JM, Schutgens REG, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Meer FJM, Fijnvandraat K, Ypma P, de Maat MPM, Leebeek FWG, Meijer K, Eikenboom J, Mathôt RAA, Cnossen MH, OPTI-CLOT Study Group.
    Thromb Haemost; 2020 Jul 25; 120(7):1056-1065. PubMed ID: 32480417
    [Abstract] [Full Text] [Related]

  • 38. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 25; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 39. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M.
    Br J Haematol; 1992 Feb 25; 80(2):214-21. PubMed ID: 1550779
    [Abstract] [Full Text] [Related]

  • 40. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
    Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S, Seldon M, Suppiah R, Teague L, Barrese G.
    Haemophilia; 2011 May 25; 17(3):463-9. PubMed ID: 21118340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.